MAM
MYGN icon

Martingale Asset Management’s Myriad Genetics MYGN Stock Holding History

Martingale Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
178,546
+13,119
+8% +$59.5K 0.02% 535
2026
Q1 		$744K Buy
165,427
+36,517
+28% +$190K 0.02% 561
2025
Q4 		$793K Buy
128,910
+54,886
+74% +$398K 0.02% 515
2025
Q3 		$535K Buy
+74,024
New +$440K 0.01% 605

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Martingale Asset Management's MYGN Position: Q2 2026 in Review

Martingale Asset Management increased its Myriad Genetics (MYGN) stake by 7.9% in Q2 2026, buying an estimated $59.5K and bringing the position to 178,546 shares worth $1.02M. The position accounts for 0.02% of the portfolio, ranked #535.

Martingale Asset Management first reported a position in MYGN in Q3 2025 and has held it in 4 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Martingale Asset Management held 178,546 shares of Myriad Genetics worth $1.02M as of Q2 2026.
  • Martingale Asset Management bought 13,119 Myriad Genetics shares in Q2 2026, an estimated $59.5K.
  • Myriad Genetics made up 0.02% of Martingale Asset Management's portfolio in Q2 2026, its #535 holding.
  • Martingale Asset Management first reported a position in Myriad Genetics in Q3 2025 and has held it in 4 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.